Thank you for Subscribing to Life Science Review Weekly Brief
Navigo Proteins deepens its partnership with ITM SE.
FREMONT, CA: “We are delighted to continue working with Navigo Proteins and building upon our productive partnership. Our high-quality radioisotopes coupled with Navigo’s Affilin® ligands have the opportunity to unlock an array of precision oncology therapeutics to help patients living with hard-to-treat tumors by positively impacting current treatment algorithms,” states Steffen Schuster, CEO of ITM. Navigo Proteins, a leading protein engineering company focused on developing optimized scaffold protein-based affinity ligands through its Precision Targeting toolbox, has extended its ongoing collaboration with ITM SE, a leading radiopharmaceutical biotechnology company. The firms will collaborate to create targeted radiopharmaceutical options for cancer treatment by combining Navigos Affilin® ligands with ITM's high-quality medical radioisotopes. The cooperation will now be strengthened further with the addition of another precision oncology targeted radionuclide therapy initiative.
Affilin® ligands enable the versatile construction of radio conjugates with short and extended half-lives for imaging and therapeutic applications. The target-specific, best-in-class Affilin® ligands are an ideal complement to ITM's precision oncology pipeline, which currently includes agents for neuroendocrine tumors, prostate cancer, glioblastoma, osteosarcoma, and bone metastases, as well as folate receptor Î positive tumors such as lung, ovarian, or breast cancer.
Henning Afflerbach, CEO of Navigo Proteins, comments, "We have very promising ongoing projects with ITM, and this continuation and expansion of our partnership validates our Affilin® based approach for creating pure and precise next-generation radiotherapeutics. Navigos Precision Targeting toolbox allows the design and development of highly homogenous, Affilin® radio conjugates with fine tunable half-lives. The long-standing, successful relationship with ITM as a leading partner in precision oncology is a further step on our way to deliver best-in-class targeted radionuclide therapies."